Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ACCV
4. AZN
5. FICO
6. GMAB
7. QQQ
8. SPCX
9. APO
10. SMMT

Go back to Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c

Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019 4:01 PM EDT

SAN FRANCISCO, May 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company's recent achievements and anticipated upcoming milestones.  

"We are excited by the continued strong momentum across our business," stated Matthew R. Patterson, Chairman and Chief Executive Officer.  "We recently presented new positive data from ASPIRO, the Phase 1/2 study of AT132 for the... More